Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214134 | 0.89 | KDM4E (0.69) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL29953598 | 0.89 | KDM4E (0.69) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL29955460 | 0.87 | HPGD (0.53) | TSHRHSP90AA1CA12CA1CA2 | |
| SCHEMBL29952513 | 0.85 | HPGD (0.55) | TSHRHSP90AA1CA12CA1CA2 | |
| SCHEMBL951604 | 0.83 | MAPT (0.55) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL9792231 | 0.82 | KDM4E (0.77) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL2207253 | 0.80 | MAPT (0.55) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL29954438 | 0.80 | MAPT (0.55) | MAPTTSHRKDM4EHTTHSP90AA1 | |
| SCHEMBL1773700 | 0.80 | SMN1; SMN2 (0.51) | MAPTHTTSMN1; SMN2KMT2A | |
| SCHEMBL4766465 | 0.79 | MAPT (0.61) | MAPTTSHRKDM4EHTTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| EP-2941425-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2015-11-11 | — | — | EP | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014106612-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | MAPT 775/4885TSHR 316/4885KDM4E 1403/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | MAPT 1125/4885TSHR 444/4885KDM4E 1635/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | MAPT 40/4885TSHR 4185/4885KDM4E 1561/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | MAPT 1991/4885TSHR 3700/4885KDM4E 2454/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | MAPT 1035/4885TSHR 3382/4885KDM4E 3971/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | MAPT 775/4885TSHR 316/4885KDM4E 1403/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | MAPT 1125/4885TSHR 444/4885KDM4E 1635/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | MAPT 1035/4885TSHR 3382/4885KDM4E 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.